|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Elan Drug Technologies (2011)
|
|
gptkbp:businessModel
|
public
|
|
gptkbp:CEO
|
gptkb:Richard_Pops
|
|
gptkbp:countryOfOperation
|
gptkb:Ireland
|
|
gptkbp:focusesOn
|
oncology
central nervous system disorders
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_Wall
|
|
gptkbp:headquartersLocation
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alkermes plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Richard_Pops
gptkb:Blair_Jackson
Craig Hopkinson
Iain Brown
Samantha Budd Haeberlein
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:manufacturingFacilities
|
gptkb:Athlone,_Ireland
|
|
gptkbp:market
|
gptkb:cancer
gptkb:major_depressive_disorder
bipolar disorder
schizophrenia
alcohol dependence
opioid dependence
|
|
gptkbp:notableProduct
|
gptkb:Aristada
gptkb:Lybalvi
gptkb:Vivitrol
|
|
gptkbp:numberOfEmployees
|
~2,200
|
|
gptkbp:operatesIn
|
gptkb:Ireland
gptkb:United_States
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:researchFacilityLocation
|
gptkb:Waltham,_Massachusetts,_USA
|
|
gptkbp:specializesIn
|
injectable medications
long-acting formulations
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:ALKS
|
|
gptkbp:subsidiary
|
Alkermes, Inc.
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_ALKS
|
|
gptkbp:website
|
https://www.alkermes.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:_ALKS
|
|
gptkbp:bfsLayer
|
8
|